Open Access
Formulation of novel niosomal repaglinide chewable tablets using coprocessed excipients: in vitro characterization, optimization and enhanced hypoglycemic activity in rats
Shahinaze A. Fouad
1
,
Mahmoud H. Teaima
2
,
Mostafa I. Gebril
3
,
Fathy I. Abd-Allah
4, 5
,
Mohamed A. El-Nabarawi
2
,
Sammar Fathy Elhabal
6
5
International Center for Bioavailability, Pharmaceutical and Clinical Research, Obour City, Cairo, Egypt
|
6
Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Modern University for Technology and Information (MTI), Mokattam, Cairo, Egypt
|
Publication type: Journal Article
Publication date: 2023-02-20
scimago Q1
wos Q1
SJR: 1.380
CiteScore: 16.4
Impact factor: 8.1
ISSN: 10717544, 15210464
PubMed ID:
36803255
General Medicine
Pharmaceutical Science
Abstract
Abstract
Repaglinide (RPG), a monotherapy insulin secretagogue used to treat diabetes mellitus-type II yet, it suffers from poor water solubility and variable bioavailability (∼ 50%) due to hepatic first pass metabolism. In this study, 2FI I-Optimal statistical design was employed to encapsulate RPG into niosomal formulations using cholesterol,span 60 and peceolTM. The optimized niosomal formulation (ONF) showed particle size 306.60 ± 84.00 nm, zeta potential −38.60 ± 1.20 mV, polydispersity index 0.48 ± 0.05 and entrapment efficiency 92.00 ± 2.60%. ONF showed > 65% RPG release that lasted for 3.5 h, and significantly higher sustained release compared to Novonorm® tablets after 6 h (p < 0.0001). TEM for ONF showed spherical vesicles with dark core and light-colored lipid bilayer membrane. RPG peaks disappeared in FTIR confirming successful RPG entrapment. To eliminate dysphagia associating conventional oral tablets, chewable tablets loaded with ONF were prepared using coprocessed excipients; Pharmaburst® 500, F-melt® and Prosolv® ODT. Tablets showed friability
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
1
2
3
|
|
|
Pharmaceutical Development and Technology
3 publications, 9.68%
|
|
|
International Journal of Nanomedicine
3 publications, 9.68%
|
|
|
Pharmaceutics
2 publications, 6.45%
|
|
|
AAPS PharmSciTech
2 publications, 6.45%
|
|
|
Journal of Drug Delivery Science and Technology
2 publications, 6.45%
|
|
|
Drug Delivery and Translational Research
2 publications, 6.45%
|
|
|
Saudi Pharmaceutical Journal
1 publication, 3.23%
|
|
|
Progress in Organic Coatings
1 publication, 3.23%
|
|
|
Drug Delivery
1 publication, 3.23%
|
|
|
Biomedicines
1 publication, 3.23%
|
|
|
Intelligent Pharmacy
1 publication, 3.23%
|
|
|
European Journal of Pharmaceutical Sciences
1 publication, 3.23%
|
|
|
Journal of Pharmaceutical Investigation
1 publication, 3.23%
|
|
|
Current Pharmaceutical Design
1 publication, 3.23%
|
|
|
Chemical Engineering Journal
1 publication, 3.23%
|
|
|
Russian Chemical Reviews
1 publication, 3.23%
|
|
|
Journal of Applied Polymer Science
1 publication, 3.23%
|
|
|
Pharmacological Reviews
1 publication, 3.23%
|
|
|
Journal of Pharmaceutical Sciences
1 publication, 3.23%
|
|
|
Journal of Drug Targeting
1 publication, 3.23%
|
|
|
International Journal of Pharmaceutics: X
1 publication, 3.23%
|
|
|
Materials Today Chemistry
1 publication, 3.23%
|
|
|
1
2
3
|
Publishers
|
2
4
6
8
10
|
|
|
Elsevier
10 publications, 32.26%
|
|
|
Taylor & Francis
8 publications, 25.81%
|
|
|
Springer Nature
6 publications, 19.35%
|
|
|
MDPI
3 publications, 9.68%
|
|
|
King Saud University
1 publication, 3.23%
|
|
|
Bentham Science Publishers Ltd.
1 publication, 3.23%
|
|
|
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 publication, 3.23%
|
|
|
Wiley
1 publication, 3.23%
|
|
|
2
4
6
8
10
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
31
Total citations:
31
Citations from 2024:
25
(80.65%)
Cite this
GOST |
RIS |
BibTex
Cite this
GOST
Copy
Fouad S. A. et al. Formulation of novel niosomal repaglinide chewable tablets using coprocessed excipients: in vitro characterization, optimization and enhanced hypoglycemic activity in rats // Drug Delivery. 2023. Vol. 30. No. 1.
GOST all authors (up to 50)
Copy
Fouad S. A., Teaima M. H., Gebril M. I., Abd-Allah F. I., El-Nabarawi M. A., Elhabal S. F. Formulation of novel niosomal repaglinide chewable tablets using coprocessed excipients: in vitro characterization, optimization and enhanced hypoglycemic activity in rats // Drug Delivery. 2023. Vol. 30. No. 1.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1080/10717544.2023.2181747
UR - https://doi.org/10.1080/10717544.2023.2181747
TI - Formulation of novel niosomal repaglinide chewable tablets using coprocessed excipients: in vitro characterization, optimization and enhanced hypoglycemic activity in rats
T2 - Drug Delivery
AU - Fouad, Shahinaze A.
AU - Teaima, Mahmoud H.
AU - Gebril, Mostafa I.
AU - Abd-Allah, Fathy I.
AU - El-Nabarawi, Mohamed A.
AU - Elhabal, Sammar Fathy
PY - 2023
DA - 2023/02/20
PB - Taylor & Francis
IS - 1
VL - 30
PMID - 36803255
SN - 1071-7544
SN - 1521-0464
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2023_Fouad,
author = {Shahinaze A. Fouad and Mahmoud H. Teaima and Mostafa I. Gebril and Fathy I. Abd-Allah and Mohamed A. El-Nabarawi and Sammar Fathy Elhabal},
title = {Formulation of novel niosomal repaglinide chewable tablets using coprocessed excipients: in vitro characterization, optimization and enhanced hypoglycemic activity in rats},
journal = {Drug Delivery},
year = {2023},
volume = {30},
publisher = {Taylor & Francis},
month = {feb},
url = {https://doi.org/10.1080/10717544.2023.2181747},
number = {1},
doi = {10.1080/10717544.2023.2181747}
}